Skip to main content

Conference Correspondent

ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
A Genetic Risk-Stratified Phase 2 Study of Fludarabine/Antibody Combinations in Symptomatic, Untreated CLL: Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance)
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Ublituximab and Ibrutinib for Previously Treated, Genetically High-Risk CLL: Results of the GENUINE Phase 3 Study
Read More
ASCO 2017 - Chronic Lymphocytic Leukemia, Conference Correspondent
Clinical Outcomes of Patients with DLBCL, FL, and Richter Transformation Treated with Ibrutinib: A Real-World Experience of Off-Label Ibrutinib Use
Read More
ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Read More
Conference Correspondent, Conference Highlights AMCP
Payers’ Perspective: Incorporating Real-World Evidence in Patient Care
Lilly Ostrovsky
Lilly Ostrovsky
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Findings from the Connect MM Registry: Changes in Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Carfilzomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Elotuzumab, Lenalidomide, and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Response-Adapted Therapy for Newly Diagnosed Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Read More
Page 3 of 8
Results 21 - 30 of 79